Target intelligence / Profile preview

NUP50 divergent transcript (NUP50-DT)

Target
NUP50-DT
Molecular classification
Other (antisense long non-coding RNA, divergent transcript), long non-coding RNA (lncRNA)
01

Overview

NUP50 divergent transcript (NUP50-DT), also known as NUP50-AS1 or NUP50 antisense RNA 1 (head to head), is a long non-coding RNA (lncRNA) that is transcribed in a divergent orientation relative to the NUP50 gene[2]. Antisense lncRNAs such as NUP50-DT are typically involved in the regulation of protein-coding genes located nearby, often by influencing transcription, mRNA stability, or chromatin state, but the precise biological function and disease associations of NUP50-DT remain poorly characterized based on currently available data. NUP50-DT should not be confused with the protein-coding gene NUP50, which encodes a nucleoporin involved in nuclear pore complex function and nucleocytoplasmic transport. There are no documented drug interactions, mechanisms of action, or established biomarker roles for NUP50-DT as of this review. Key points: - NUP50-DT is a non-coding RNA transcript, not a receptor, enzyme, or typical therapeutic target. - No direct evidence ties it to disease mechanisms or clinical interventions at this time. - Most information concerns its annotation and relationship to the canonical NUP50 gene, with function inferred by analogy to other antisense long non-coding RNAs[2].

Other names
NUP50-AS1NUP50 antisense RNA 1 (head to head)NUP50-DT
02

Biological functions

Currently uncharacterizedlikely involved in gene regulationinfluencing transcriptioninfluencing mRNA stabilityinfluencing chromatin state
03

Disease associations

Other (no direct disease association documented)poorly characterized

Beyond the preview

Go deeper on NUP50 divergent transcript (NUP50-DT).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on NUP50 divergent transcript (NUP50-DT).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call